These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 36240831)
21. Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign. Honarvar B; Moghadami M; Moattari A; Emami A; Odoomi N; Bagheri Lankarani K PLoS One; 2013; 8(1):e55043. PubMed ID: 23383049 [TBL] [Abstract][Full Text] [Related]
23. Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran. Izadi S; Zahraei SM; Mokhtari-Azad T Hum Vaccin Immunother; 2018 Jun; 14(6):1412-1416. PubMed ID: 29420120 [TBL] [Abstract][Full Text] [Related]
24. Leveraging a national biorepository in Zambia to assess measles and rubella immunity gaps across age and space. Carcelen AC; Winter AK; Moss WJ; Chilumba I; Mutale I; Chongwe G; Monze M; Mulundu G; Nkamba H; Mwansa FD; Mulenga L; Rhoda DA; Hayford K; Mutembo S Sci Rep; 2022 Jun; 12(1):10217. PubMed ID: 35715547 [TBL] [Abstract][Full Text] [Related]
25. Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016. Subaiya S; Tabu C; N'ganga J; Awes AA; Sergon K; Cosmas L; Styczynski A; Thuo S; Lebo E; Kaiser R; Perry R; Ademba P; Kretsinger K; Onuekwusi I; Gary H; Scobie HM PLoS One; 2018; 13(7):e0199786. PubMed ID: 29965975 [TBL] [Abstract][Full Text] [Related]
26. Burden of congenital rubella syndrome (CRS) in India based on data from cross-sectional serosurveys, 2017 and 2019-20. Shanmugasundaram D; Awasthi S; Dwibedi B; Geetha S; Jain M; Malik S; Patel B; Singh H; Tripathi S; Viswanathan R; Agarwal A; Bonu R; Jain S; Jena SK; Priyasree J; Pushpalatha K; Ali S; Biswas D; Jain A; Narang R; Madhuri S; George S; Kaduskar O; Kiruthika G; Sabarinathan R; Sapakal G; Gupta N; Murhekar MV PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009608. PubMed ID: 34297716 [TBL] [Abstract][Full Text] [Related]
27. A 16-year review of seroprevalence studies on measles and rubella. Dimech W; Mulders MN Vaccine; 2016 Jul; 34(35):4110-4118. PubMed ID: 27340097 [TBL] [Abstract][Full Text] [Related]
28. Status of coverage of MR vaccination, after supplementary immunization activities in a rural area of South India: a rapid immunization coverage survey. Newtonraj A; Vincent A; Selvaraj K; Manikandan M Rural Remote Health; 2019 Sep; 19(3):5261. PubMed ID: 31529972 [TBL] [Abstract][Full Text] [Related]
30. Vaccination coverage survey and seroprevalence among forcibly displaced Rohingya children, Cox's Bazar, Bangladesh, 2018: A cross-sectional study. Feldstein LR; Bennett SD; Estivariz CF; Cooley GM; Weil L; Billah MM; Uzzaman MS; Bohara R; Vandenent M; Adhikari JM; Leidman E; Hasan M; Akhtar S; Hasman A; Conklin L; Ehlman D; Alamgir A; Flora MS PLoS Med; 2020 Mar; 17(3):e1003071. PubMed ID: 32231368 [TBL] [Abstract][Full Text] [Related]
31. Challenges Addressing Inequalities in Measles Vaccine Coverage in Zambia through a Measles-Rubella Supplementary Immunization Activity during the COVID-19 Pandemic. Yang Y; Kostandova N; Mwansa FD; Nakazwe C; Namukoko H; Sakala C; Bobo P; Masumbu PK; Nachinga B; Ngula D; Carcelen AC; Prosperi C; Winter AK; Moss WJ; Mutembo S Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992192 [TBL] [Abstract][Full Text] [Related]
32. Rubella and measles seroprevalence among women of childbearing age, Argentina, 2002. Dayan GH; Panero MS; Urquiza A; Molina M; Prieto S; Del Carmen Perego M; Scagliotti G; Galimberti D; Carroli G; Wolff C; Bi D; Bellini W; Icenogle J; Reef S Epidemiol Infect; 2005 Oct; 133(5):861-9. PubMed ID: 16181506 [TBL] [Abstract][Full Text] [Related]
33. Seroprevalence of measles and rubella antibodies in pregnant women Haiti, 2012. Fitter DL; Anselme R; Paluku G; Rey G; Flannery B; Tohme RA; Marston BJ; Griswold M; Boncy J; Vertefeuille JF Vaccine; 2013 Dec; 32(1):69-73. PubMed ID: 24188751 [TBL] [Abstract][Full Text] [Related]
34. [Immunity coverage against measles, rubella and parotiditis viruses in a juvenile population in Leon, Spain]. Suárez J; Castañeda MR; Gutiérrez CB; Rodríguez Barbosa JI; Tascón RI; Rodríguez Ferri EF Med Clin (Barc); 1993 Oct; 101(13):484-7. PubMed ID: 8231381 [TBL] [Abstract][Full Text] [Related]
35. Comparison of population-based measles-rubella immunoglobulin G antibody prevalence between 2014 and 2019 in Lao People's Democratic Republic: Impacts of the national immunization program. Miyano S; Vynnycky E; Pattamavone C; Ichimura Y; Mori Y; Nouanthong P; Phounphenghack K; Tengbriacheu C; Khamphaphongphane B; Franzel L; Yang TU; Raaijimarkers H; Komada K; Ota T; Funato M; Takeda M; Hachiya M Int J Infect Dis; 2023 Apr; 129():70-77. PubMed ID: 36758852 [TBL] [Abstract][Full Text] [Related]
36. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. Poethko-Müller C; Mankertz A PLoS One; 2012; 7(8):e42867. PubMed ID: 22880124 [TBL] [Abstract][Full Text] [Related]
37. Factors affecting non-coverage of measles-rubella vaccination among children aged 9-59 months in Tanzania. Mkopi A; Mtenga S; Festo C; Mhalu G; Shabani J; Tillya R; Masemo A; Kheir K; Nassor M; Mwengee W; Lyimo D; Masanja H Vaccine; 2021 Oct; 39(41):6041-6049. PubMed ID: 34531077 [TBL] [Abstract][Full Text] [Related]